EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions

Boris Dinkov, Nikolinka Koleva iD, Galya Stavreva iD

Pharmaceutics · 16.09.2026 · 18 (9) · 1171

DOI: 10.3390/pharmaceutics18091171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 16.09.2026. Verfasst von Boris Dinkov und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral absorption remains challenging for peptides, proteins, and other drug substances with limited stability or permeability. Sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), also known as salcaprozate sodium, is an oral permeation enhancer used in approved drug products. This review summarizes the physicochemical properties and mechanisms of action of SNAC and evaluates its clinical and emerging preclinical applications. A structured literature search was conducted in PubMed and Scopus, supplemented as needed with ClinicalTrials.gov and regulatory documents. The search covered 2015–2026, with earlier key publications included where necessary for historical context. After screening, 71 sources were included in the narrative synthesis. The review examines the proposed mechanisms of SNAC-mediated permeation enhancement, including local pH modulation, membrane-mediated effects, peptide self-association, and context-dependent effects on epithelial permeability. Clinical evidence is summarized for oral semaglutide, cyanocobalamin, unfractionated heparin, ibandronate, and investigational peptide products. Emerging applications beyond metabolic diseases are discussed together with formulation strategies and safety considerations. Recent preclinical findings suggesting changes in gut microbiota and inflammatory markers are critically evaluated in the context of the available clinical safety experience, while their relevance to humans remains unconfirmed. Overall, SNAC reliably enhances permeation in vitro and in vivo, yet the resulting oral bioavailability remains low and variable and is strongly dependent on payload, formulation, and gastrointestinal conditions. Long-term safety and the clinical relevance of recent preclinical microbiome findings remain important areas for future investigation.

Schlagwörter

Stichwörter der Autor:innen

SNACgastric absorptionoral bioavailabilityoral peptide deliverypermeation enhancersalcaprozate sodium

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria.
  • Clinic of Endocrinology and Metabolic Diseases, University Hospital "Dr. Georgi Stranski", 5800 Pleven, Bulgaria.
  • Center of Competence in Personalized Medicine, 3D and Telemedicine, Robotic and Minimally Invasive Surgery "Leonardo da Vinci", Medical University, 5800 Pleven, Bulgaria.

ORCID-Profile: Nikolinka Koleva, Galya Stavreva

Zitieren

APA

Dinkov, B., Koleva, N., & Stavreva, G. (2026). Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions. Pharmaceutics, 18(9), 1171. https://doi.org/10.3390/pharmaceutics18091171

Vancouver

Dinkov B, Koleva N, Stavreva G. Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions. Pharmaceutics. 2026;18(9):1171. doi:10.3390/pharmaceutics18091171

BibTeX
@article{Dinkov2026,
  author = {Dinkov, Boris and Koleva, Nikolinka and Stavreva, Galya},
  title = {Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1171},
  doi = {10.3390/pharmaceutics18091171}
}
Kostenlos starten →